Granulomatous mycosis fungoides responsive to acitretin and <scp>UVA</scp>1 treatment

Shao, E.; Mortimore, Rohan; Sander, Christina S.; Wheller, Laura

doi:10.1111/ajd.12994

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More studies are needed for further evaluation of this treatment. UVA1, although reported in a few cohort studies as an efective treatment [17][18][19][20][21][22][23][24], is a relatively expensive and time-consuming technology.…”

Section: Dermatologic Terapymentioning

confidence: 99%

“…However, availability is limited to certain centers, as it is a treatment with higher cost, and is unsuitable for patients with facial involvement, and with physical disabilities preventing them from soaking in a bath [13][14][15]. Data regarding the use of other UVA-based treatments such as broadband UVA is sparse [16], while UVA1, although being an efective treatment according to several cohort studies and a few case reports, is a relatively expensive technology and is not widely available worldwide [17][18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultraviolet A Combined with Narrow‐Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow‐Band Ultraviolet B: A Retrospective Cohort Study

Amitay-Laish,

Prag Naveh,

Holzman

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and for early-stage non-FMF refractory to narrow-band ultraviolet B (NBUVB). However, PUVA has a problematic safety profile. Literature on the treatment with the combination of UVA and NBUVB for MF is sparse. Objective. To evaluate the effectiveness of UVA combined with NBUVB for early-stage MF, specifically for FMF and NBUVB-refractory non-FMF, in adult and pediatric patients. Methods. A retrospective analysis was conducted for patients treated with UVA combined with NBUVB at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults and 16 pediatric patients. The overall response rate (ORR) of 39 patients with early-FMF (25 adults and 14 children) was 95%, and the complete response (CR) was 62%. No significant differences in ORR/CR rates were noted between adult and pediatric patients. Of 12 patients with non-FMF (10 adults and 2 children), the ORR was 83% and the CR was 50%. In 17 patients (8 FMF and 9 non-FMF), prior NBUVB therapy resulted in partial response/stable disease; yet, UVA + NBUVB led to CR in 9 patients (4 FMF and 5 non-FMF). Side effects were minimal. Conclusion. Combined UVA and NBUVB is a good alternative to PUVA for adult or pediatric patients with early-stage MF , with FMF or non-FMF refractory to NBUVB.

show abstract